These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25768011)

  • 1. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
    Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
    PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
    Lath DL; Buckle CH; Evans HR; Fisher M; Down JM; Lawson MA; Chantry AD
    PLoS One; 2018; 13(6):e0199517. PubMed ID: 29924867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.
    Paton-Hough J; Chantry AD; Lawson MA
    Bone; 2015 Aug; 77():57-68. PubMed ID: 25868800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
    J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice.
    Miyakawa Y; Ohnishi Y; Tomisawa M; Monnai M; Kohmura K; Ueyama Y; Ito M; Ikeda Y; Kizaki M; Nakamura M
    Biochem Biophys Res Commun; 2004 Jan; 313(2):258-62. PubMed ID: 14684154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of animal models in multiple myeloma.
    Libouban H
    Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an in vivo model of human multiple myeloma bone disease.
    Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD
    Blood; 1996 Feb; 87(4):1495-501. PubMed ID: 8608240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
    Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
    Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.
    Huang SY; Tien HF; Su FH; Hsu SM
    Am J Pathol; 2004 Feb; 164(2):747-56. PubMed ID: 14742278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):967-72. PubMed ID: 17956671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.
    Schueler J; Wider D; Klingner K; Siegers GM; May AM; Wäsch R; Fiebig HH; Engelhardt M
    PLoS One; 2013; 8(11):e79939. PubMed ID: 24223204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models.
    Paton-Hough J; Tazzyman S; Evans H; Lath D; Down JM; Green AC; Snowden JA; Chantry AD; Lawson MA
    J Bone Miner Res; 2019 May; 34(5):783-796. PubMed ID: 30320927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer.
    Rabin N; Kyriakou C; Coulton L; Gallagher OM; Buckle C; Benjamin R; Singh N; Glassford J; Otsuki T; Nathwani AC; Croucher PI; Yong KL
    Leukemia; 2007 Oct; 21(10):2181-91. PubMed ID: 17657224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment.
    Fryer RA; Graham TJ; Smith EM; Walker-Samuel S; Morgan GJ; Robinson SP; Davies FE
    PLoS One; 2013; 8(2):e57641. PubMed ID: 23437401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vivo model of human multiple myeloma bone disease.
    Alsina M; Boyce BF; Mundy GR; Roodman GD
    Stem Cells; 1995 Aug; 13 Suppl 2():48-50. PubMed ID: 8520511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.
    Reinholz MM; Zinnen SP; Dueck AC; Dingli D; Reinholz GG; Jonart LA; Kitzmann KA; Bruzek AK; Negron V; Abdalla AK; Arendt BK; Croatt AJ; Sanchez-Perez L; Sebesta DP; Lönnberg H; Yoneda T; Nath KA; Jelinek DF; Russell SJ; Ingle JN; Spelsberg TC; Dixon HB; Karpeisky A; Lingle WL
    Bone; 2010 Jul; 47(1):12-22. PubMed ID: 20233612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Establishment of xenotransplated mouse model using primary multiple myeloma cells].
    Liu CY; Zhang L; Wang N; Wang D; Geng Z; Xu DM; Li CR; Zhou JF; Huang L
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):195-9. PubMed ID: 22781606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.